OFFICIAL PUBLICATION OF

by its subsidiary APPco

New antibiotic from MSD

Megan Haggan 19/11/2015

Schedule 3 - pharmacist holding out pill bottles

MSD today announced that its new antibiotic has been registered by the Therapeutic Goods Administration for the treatment of common and problematic gram-negative pathogens. The first new antibiotic registered in Australia in almost ten years for the treatment of gram-negative pathogens, ZERBAXA (ceftolozane/tazobactam) is approved for use in hospitals for the treatment of complicated intra-abdominal

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Recent Comments
Popular Posts

‘Consumer confusion, pharmacist frustration’ if current system continues

The first and foremost role of "expanded scope" is the HMR and collaborative medication management. A clear no brainer which…

Big Pharma

‘I can feel the walls closing in on me as this snowballs’

I'm yet to encounter a corporate provider, Debbie, with the benefits you describe around quality improvement with the corporate business…

Kelly Abbott

‘Consumer confusion, pharmacist frustration’ if current system continues

I welcome Mark's move, at least someone talks about it. But like any push at the forefront, it comes with…

Benjamyn Sung

‘I can feel the walls closing in on me as this snowballs’

I would argue quality varies in any profession. Most GPs will not refer to a provider where the quality is…

Big Pharma

New antibiotic from MSD

Previous Time allows Regulation Impact Statement on codeine: PSA

Next Australia needs 'cultural shift' on antibiotics: NPS

In the beginning

The signs of ageing

Hyperpigmentation

How to avoid dry skin

MENU

Previous Time allows Regulation Impact Statement on codeine: PSA

Next Australia needs 'cultural shift' on antibiotics: NPS

Related Posts

MENU

Hi there! 👋 Looks like you’re not logged in.